ACADIA Pharmaceuticals is trading at $25.33, down -4.09% on September 23, 2026, with no fresh company-specific announcement identified to explain the decline.
- Available coverage points to investor focus on an upcoming remlifanserin clinical readout, but it is not a new catalyst for this session.
- The broader market is weaker, while biotechnology is outperforming; the immediate cause of the decline remains unclear.